New longevity economics data: Slowing biological aging post-50 adds 3.6 years to lifespan with $4M economic value per person. This quantifies the ROI on aging interventions beyond just health metrics - we're talking measurable GDP impact from extended productive years. The math validates why longevity biotech is getting serious VC attention: it's not just about living longer, it's about economic multipliers from healthspan extension. Puts concrete numbers on why protocols like Bryan Johnson's Blueprint matter at scale.